Cirmtuzumab - Oncternal Therapeutics

Drug Profile

Cirmtuzumab - Oncternal Therapeutics

Alternative Names: UC-961

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Oncternal Therapeutics, Inc.; University of California, San Diego
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Preclinical Breast cancer; Ovarian cancer

Most Recent Events

  • 25 Mar 2018 Oncternal Therapeutics initiates enrolment in a Ib/II trial in Chronic lymphocytic leukaemia and Mantle cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (NCT03420183)
  • 03 Jan 2018 Phase-I/II clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT03088878)
  • 03 Jan 2018 Phase-I/II clinical trials in Mantle cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03088878)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top